We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Impax, Medicis Clear Up Acne Patent Dispute

Law360 (December 2, 2008, 12:00 AM EST) -- Impax Laboratories Inc. will be able to move forward with marketing a generic version of the acne medication Solodyn now that the company has resolved its patent battle with Medicis Pharmaceutical Corp.

The companies said Monday they had reached a settlement and license agreement, which ends litigation over Medicis’ patent covering Solodyn and allows Impax to launch a generic version of the drug no later than November 2011. Once Impax starts selling the drug, it may be required to pay Medicis a royalty fee.

The deal...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.